Gilead Sciences' Q1 2025 earnings reveal challenges in oncology and Veklury sales, while HIV therapies remain strong. See why ...

The dollar experienced a volatile week, initially dropping due to President Trump's criticism of the Federal Reserve, then surging on hopes of trade de-escalation with China. However, uncertainty ...